VistaGen Therapeutics, Inc. P/B ratio

P/B ratio of VTGN for past 10 years: annual, quarterly and twelve month trailing (TTM) including P/B ratio growth rates and interactive chart. Measures the relationship between price and book value per share. Book value is the equity or owner's capital that is invested in a business. If a stock has a price of $10 and a book value per share of $10, the ratio is 1. Stock selling below a P/B of 1 can be a bargain, as the market price has declined below the net asset value of the business. It is more applicable to financial companies like banks and insurers, as their assets and liabilities are valued at market and the book value thus more accuraterly represents reality.


Highlights and Quick Summary

Current P/B ratio of VistaGen Therapeutics, Inc. is 24.13 (as of March 30, 2017)
  • P/B ratio for the quarter ending December 30, 2020 was 1.68 (a -84.93% decrease compared to previous quarter)
  • Year-over-year quarterly P/B ratio increased by Infinity%
  • Annual P/B ratio for 2017 was 24.13 (a Infinity% increase from previous year)
  • Annual P/B ratio for 2013 was 0.0 (a NaN% decrease from previous year)
  • Annual P/B ratio for 2012 was 0.0 (a NaN% decrease from previous year)
Visit stockrow.com/VTGN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical P/B ratio of VistaGen Therapeutics, Inc.

Most recent P/B ratioof VTGN including historical data for past 10 years.

Interactive Chart of P/B ratio of VistaGen Therapeutics, Inc.

VistaGen Therapeutics, Inc. P/B ratio for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 1.68 11.13
2017 24.13
2016 12.1
2013 0.0
2012 0.0 0.0 0.0
2011 0.0 0.0 0.0 0.0 0.0
2010 0.0 0.0

Business Profile of VistaGen Therapeutics, Inc.

Sector: Healthcare
Industry: Biotechnology
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, panic, and others. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license and option agreements with Pherin Pharmaceuticals, Inc.; license and collaboration agreement with EverInsight Therapeutics Inc.; and license and sublicense agreement with BlueRock Therapeutics, LP. The company was founded in 1998 and is headquartered in South San Francisco, California.